Combination therapy

Details for Australian Patent Application No. 2008316283 (hide)

Owner Merck Frosst Canada Ltd.

Inventors Thibert, Roch

Agent Spruson & Ferguson

Pub. Number AU-A-2008316283

PCT Pub. Number WO2009/052624

Priority 61/000,327 25.10.07 US

Filing date 23 October 2008

Wipo publication date 30 April 2009

International Classifications

A61K 31/47 (2006.01) - Quinolines

A61K 31/444 (2006.01)

A61K 31/573 (2006.01)

A61K 31/58 (2006.01) - containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin

A61P 11/06 (2006.01) Drugs for disorders of the respiratory system

Event Publications

6 May 2010 PCT application entered the National Phase

  PCT publication WO2009/052624 Priority application(s): WO2009/052624

27 May 2010 Amendment Made

  The nature of the amendment is: Amend the invention title to read Inhalation compositions comprising montelukast acid and a PDE-4 inhibitor or an inhaled corticosteroid

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008316284-Novel crystalline salts of montelukast

2008316278-Method of applying a thermally settable coating to a patterned substrate